Head and Neck Tumors

  • Diana L. DiesenEmail author
  • Michael A. Skinner


Head and neck tumors present a diagnostic dilemma for pediatrician and surgeons. While a majority of these tumors are benign, an understanding of the fundamentals of surgical oncology is needed when approaching these tumors to ensure proper assessment and treatment. Benign lesions like thyroglossal duct cysts and brachial cleft cyst are treated by simple excision. Cervical adenopathy, while often benign, may result from infection or neoplasm such as lymphoma. Solid tumors of the head and neck include thyroid tumors, neuroblastoma, rhabdomyosarcoma, non-rhabdomyosarcomas, germ cell tumors, salivary gland tumors and nasopharyngeal carcinoma. Treatment of these neoplastic processes requires a multi-disciplinary approach including pediatricians, surgeons, medical oncologist, and radiation oncologists.


Cervical adenopathy Hodgkin’s disease Non-Hodgkin’s lymphoma Thyroid cancer Neuroblastoma Rhabdomyosarcoma Sarcomas Salivary gland tumors Nasopharyngeal carcinoma 


  1. 1.
    Herzog LW. Prevalence of lymphadenopathy of the head and neck in infants and children. Clin Pediatr (Phila). 1983;22(7):485–7.CrossRefGoogle Scholar
  2. 2.
    Torsiglieri Jr AJ, Tom LW, Ross 3rd AJ, Wetmore RF, Handler SD, Potsic WP. Pediatric neck masses: guidelines for evaluation. Int J Pediatr Otorhinolaryngol. 1988;16(3):199–210.PubMedCrossRefGoogle Scholar
  3. 3.
    Soldes OS, Younger JG, Hirschl RB. Predictors of malignancy in childhood peripheral lymphadenopathy. J Pediatr Surg. 1999;34(10):1447–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Lake AM, Oski FA. Peripheral lymphadenopathy in childhood. Ten-year experience with excisional biopsy. Am J Dis Child. 1978;132(4):357–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Knight PJ, Mulne AF, Vassy LE. When is lymph node biopsy indicated in children with enlarged peripheral nodes? Pediatrics. 1982;69(4):391–6.PubMedGoogle Scholar
  6. 6.
    Jackson LA, Perkins BA, Wenger JD. Cat scratch disease in the United States: an analysis of three national databases. Am J Public Health. 1993;83(12):1707–11.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Moussatos GH, Baffes TG. Cervical masses in infants and children. Pediatrics. 1963;32:251–6.PubMedGoogle Scholar
  8. 8.
    Derias NW, Chong WH, O’Connor AF. Fine needle aspiration cytology of a head and neck swelling in a child: a non-invasive approach to diagnosis. J Laryngol Otol. 1992;106(8):755–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Mobley DL, Wakely Jr PE, Frable MA. Fine-needle aspiration biopsy: application to pediatric head and neck masses. Laryngoscope. 1991;101(5):469–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Wakely Jr PE, Kardos TF, Frable WJ. Application of fine needle aspiration biopsy to pediatrics. Hum Pathol. 1988;19(12):1383–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Yamauchi T, Ferrieri P, Anthony BF. The aetiology of acute cervical adenitis in children: serological and bacteriological studies. J Med Microbiol. 1980;13(1):37–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Brook I. Aerobic and anaerobic bacteriology of cervical adenitis in children. Clin Pediatr (Phila). 1980;19(10):693–6.CrossRefGoogle Scholar
  13. 13.
    Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans. 1823;17:69.Google Scholar
  14. 14.
    Reed D. On the pathological changes in Hodgkins’s disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10:133.Google Scholar
  15. 15.
    Sternberg C. Uber eine Eingenartige unter dem Bilde der Pseudoleukmie verlaufende Tuberculose des lymphatischen. Apparates Z Heilkd. 1898;19:21.Google Scholar
  16. 16.
    Percy C, Smith M, Linet M, et al. In: Ries L, Smith M, Gurney J, editors. Cancer incidence and survival among children and adolescents: United States SEER Program, 1975-1995. Bethesda: National Cancer Institute; 1999.Google Scholar
  17. 17.
    Correa P, O’Conor GT. Epidemiologic patterns of Hodgkin’s disease. Int J Cancer. 1971;8(2):192–201.PubMedCrossRefGoogle Scholar
  18. 18.
    Mack TM, Cozen W, Shibata DK, Weiss LM, Nathwani BN, Hernandez AM, et al. Concordance for Hodgkin’s disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med. 1995;332(7):413–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Robertson SJ, Lowman JT, Grufferman S, Kostyu D, van der Horst CM, Matthews TJ, et al. Familial Hodgkin’s disease. A clinical and laboratory investigation. Cancer. 1987;59(7):1314–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Ferraris AM, Racchi O, Rapezzi D, Gaetani GF, Boffetta P. Familial Hodgkin’s disease: a disease of young adulthood? Ann Hematol. 1997;74(3):131–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Haluska FG, Brufsky AM, Canellos GP. The cellular biology of the Reed-Sternberg cell. Blood. 1994;84(4):1005–19.PubMedGoogle Scholar
  22. 22.
    Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin’s disease. N Engl J Med. 1989;320(8):502–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin’s disease. Cancer Res. 1966;26(6):1063–83.PubMedGoogle Scholar
  24. 24.
    Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP, et al. Hodgkin’s lymphoma: the pathologist’s viewpoint. J Clin Pathol. 2002;55(3):162–76.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Atkinson MK, McElwain TJ, Peckham MJ, Thomas PP. Hypertrophic pulmonary osteoarthropathy in Hodgkin’s disease: reversal with chemotherapy. Cancer. 1976;38(4):1729–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Kebudi R, Ayan I, Erseven G, Gorgun O, Darendeliler E, Celik A. Hypertrophic osteoarthropathy and intrathoracic Hodgkin disease of childhood. Med Pediatr Oncol. 1997;29(6):578–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Seymour JF. Splenomegaly, eosinophilia, and pruritis: Hodgkin’s disease, or…? Blood. 1997;90(4):1719–20.PubMedGoogle Scholar
  28. 28.
    Cavalli F. Rare syndromes in Hodgkin’s disease. Ann Oncol. 1998;9 Suppl 5:S109–13.PubMedCrossRefGoogle Scholar
  29. 29.
    Stefanato CM, Reyes-Mugica M. Masked Hodgkin’s disease: the pruriginous disguise. Pediatr Hematol Oncol. 1996;13(3):293–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI. The impact of Hodgkin’s disease on the immune system. Semin Oncol. 1990;17(6):673–82.PubMedGoogle Scholar
  31. 31.
    Sonnenblick M, Kramer R, Hershko C. Corticosteroid responsive immune thrombocytopenia in Hodgkin’s disease. Oncology. 1986;43(6):349–53.PubMedCrossRefGoogle Scholar
  32. 32.
    Bradley SJ, Hudson GV, Linch DC. Idiopathic thrombocytopenic purpura in Hodgkin’s disease: a report of eight cases. Clin Oncol (R Coll Radiol). 1993;5(6):355–7.CrossRefGoogle Scholar
  33. 33.
    Stein H, Mann R, Delsol G, et al. In: Jaffe E, Harris N, Stein H, Vardiman J, editors. World Health Organization classification of tumours. Pathology and genetics of tumours and haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.Google Scholar
  34. 34.
    Pappa VI, Hussain HK, Reznek RH, Whelan J, Norton AJ, Wilson AM, et al. Role of image-guided core-needle biopsy in the management of patients with lymphoma. J Clin Oncol. 1996;14(9):2427–30.PubMedGoogle Scholar
  35. 35.
    Ben-Yehuda D, Polliack A, Okon E, Sherman Y, Fields S, Lebenshart P, et al. Image-guided core-needle biopsy in malignant lymphoma: experience with 100 patients that suggests the technique is reliable. J Clin Oncol. 1996;14(9):2431–4.PubMedGoogle Scholar
  36. 36.
    Perger L, Lee EY, Shamberger RC. Management of children and adolescents with a critical airway due to compression by an anterior mediastinal mass. J Pediatr Surg. 2008;43(11):1990–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Baker LL, Parker BR, Donaldson SS, Castellino RA. Staging of Hodgkin disease in children: comparison of CT and lymphography with laparotomy. AJR Am J Roentgenol. 1990;154(6):1251–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Rostock RA, Siegelman SS, Lenhard RE, Wharam MD, Order SE. Thoracic CT scanning for mediastinal Hodgkin’s disease: results and therapeutic implications. Int J Radiat Oncol Biol Phys. 1983;9(10):1451–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Hanna SL, Fletcher BD, Boulden TF, Hudson MM, Greenwald CA, Kun LE. MR imaging of infradiaphragmatic lymphadenopathy in children and adolescents with Hodgkin disease: comparison with lymphography and CT. J Magn Reson Imaging. 1993;3(3):461–70.PubMedCrossRefGoogle Scholar
  40. 40.
    Robertson VL, Anderson CS, Keller FG, Halkar R, Goodman M, Marcus RB, et al. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2011;80(2):324–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Hernandez-Pampaloni M, Takalkar A, Yu JQ, Zhuang H, Alavi A. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol. 2006;36(6):524–31.PubMedCrossRefGoogle Scholar
  42. 42.
    Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31(11):1860–1.PubMedGoogle Scholar
  43. 43.
    Kaplan HS. Essentials of staging and management of the malignant lymphomas. Semin Roentgenol. 1980;15(3):219–26.PubMedCrossRefGoogle Scholar
  44. 44.
    Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, et al. Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol. 1986;4(9):1295–306.PubMedGoogle Scholar
  45. 45.
    Donaldson SS, Link MP, Weinstein HJ, Rai SN, Brain S, Billett AL, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol. 2007;25(3):332–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Schellong G, Potter R, Bramswig J, Wagner W, Prott FJ, Dorffel W, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin’s Disease Study Group. J Clin Oncol. 1999;17(12):3736–44.PubMedGoogle Scholar
  47. 47.
    Thomson AB, Wallace WH. Treatment of paediatric Hodgkin’s disease: a balance of risks. Eur J Cancer. 2002;38(4):468–77.PubMedCrossRefGoogle Scholar
  48. 48.
    Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051–9.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Kelly KM, Sposto R, Hutchinson R, Massey V, McCarten K, Perkins S, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children’s Oncology Group. Blood. 2011;117(9):2596–603.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Harris RE, Termuhlen AM, Smith LM, Lynch J, Henry MM, Perkins SL, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children’s Oncology Group study A5962. Biol Blood Marrow Transplant. 2011;17(2):249–58.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol. 2004;22(22):4532–40.PubMedCrossRefGoogle Scholar
  52. 52.
    Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin’s disease: results of a prospective clinical trial. J Clin Oncol. 2002;20(14):3081–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Smith RS, Chen Q, Hudson MM, Link MP, Kun L, Weinstein H, et al. Prognostic factors for children with Hodgkin’s disease treated with combined-modality therapy. J Clin Oncol. 2003;21(10):2026–33.PubMedCrossRefGoogle Scholar
  54. 54.
    Gehan EA, Sullivan MP, Fuller LM, Johnston J, Kennedy P, Fryer C, et al. The intergroup Hodgkin’s disease in children. A study of stages I and II. Cancer. 1990;65(6):1429–37.PubMedCrossRefGoogle Scholar
  55. 55.
    Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93(8):618–29.PubMedCrossRefGoogle Scholar
  56. 56.
    Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6):1806–16.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Magrath I. In: Pizza P, Poplack D, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins; 1993.Google Scholar
  58. 58.
    Magrath IT. African Burkitt’s lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol. 1991;13(2):222–46.PubMedCrossRefGoogle Scholar
  59. 59.
    Magrath I. The pathogenesis of Burkitt’s lymphoma. Adv Cancer Res. 1990;55:133–270.PubMedCrossRefGoogle Scholar
  60. 60.
    McClain KL, Joshi VV, Murphy SB. Cancers in children with HIV infection. Hematol Oncol Clin North Am. 1996;10(5):1189–201.PubMedCrossRefGoogle Scholar
  61. 61.
    Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112(12):4384–99.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Cleary ML. Oncogenic conversion of transcription factors by chromosomal translocations. Cell. 1991;66(4):619–22.PubMedCrossRefGoogle Scholar
  63. 63.
    Magrath I, Bhatia K. The non-Hodgkin lymphomas. 2nd ed. Magrath I, editor. London: Arnold.Google Scholar
  64. 64.
    Bernheim A, Berger R, Lenoir G. Cytogenetic studies on African Burkitt’s lymphoma cell lines: t(8;14), t(2;8) and t(8;22) translocations. Cancer Genet Cytogenet. 1981;3(4):307–15.PubMedCrossRefGoogle Scholar
  65. 65.
    Gu W, Bhatia K, Magrath IT, Dang CV, Dalla-Favera R. Binding and suppression of the Myc transcriptional activation domain by p107. Science. 1994;264(5156):251–4.PubMedCrossRefGoogle Scholar
  66. 66.
    ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G, Croce CM. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science. 1983;222(4622):390–3.PubMedCrossRefGoogle Scholar
  67. 67.
    Gutierrez MI, Bhatia K, Barriga F, Diez B, Muriel FS, de Andreas ML, et al. Molecular epidemiology of Burkitt’s lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood. 1992;79(12):3261–6.PubMedGoogle Scholar
  68. 68.
    Shiramizu B, Barriga F, Neequaye J, Jafri A, Dalla-Favera R, Neri A, et al. Patterns of chromosomal breakpoint locations in Burkitt’s lymphoma: relevance to geography and Epstein-Barr virus association. Blood. 1991;77(7):1516–26.PubMedGoogle Scholar
  69. 69.
    Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7837–41.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Magrath IT, Ziegler JL. Bone marrow involvement in Burkitt’s lymphoma and its relationship to acute B-cell leukemia. Leuk Res. 1980;4(1):33–59.PubMedCrossRefGoogle Scholar
  71. 71.
    Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A. 1991;88(10):4367–71.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ. Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science. 1991;253(5015):79–82.PubMedCrossRefGoogle Scholar
  73. 73.
    Burkitt D. Burkitt’s Lymphoma. Burkitt DP Wright DH, editor. Edinburgh: Livingstone; 1970.Google Scholar
  74. 74.
    Sariban E, Donahue A, Magrath IT. Jaw involvement in American Burkitt’s Lymphoma. Cancer. 1984;53(8):1777–82.PubMedCrossRefGoogle Scholar
  75. 75.
    Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.PubMedCrossRefGoogle Scholar
  77. 77.
    Burkhardt B, Oschlies I, Klapper W, Zimmermann M, Woessmann W, Meinhardt A, et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia. 2011;25(1):153–60.PubMedCrossRefGoogle Scholar
  78. 78.
    Mann G, Attarbaschi A, Burkhardt B, Niggli F, Klapper W, Ludwig WD, et al. Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma. Br J Haematol. 2007;139(3):443–9.PubMedGoogle Scholar
  79. 79.
    Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95(2):416–21.PubMedGoogle Scholar
  80. 80.
    Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736–43.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol. 2007;25(25):3915–22.PubMedCrossRefGoogle Scholar
  82. 82.
    Poirel HA, Cairo MS, Heerema NA, Swansbury J, Auperin A, Launay E, et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009;23(2):323–31.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, Lyden ER, et al. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children’s Oncology Group study CCG-5961. Br J Haematol. 2010;148(4):600–10.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773–80.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332–9.PubMedGoogle Scholar
  86. 86.
    Murphy S, Fairclough D, Hutchison R. Non-Hodgkin’s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol. 1989;7:186–93.PubMedGoogle Scholar
  87. 87.
    Pui CH, Ip SH, Kung P, Dodge RK, Berard CW, Crist WM, et al. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin’s lymphoma. Blood. 1987;70(3):624–8.PubMedGoogle Scholar
  88. 88.
    Wagner DK, Kiwanuka J, Edwards BK, Rubin LA, Nelson DL, Magrath IT. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol. 1987;5(8):1262–74.PubMedGoogle Scholar
  89. 89.
    Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, et al. Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13(2):359–72.PubMedGoogle Scholar
  90. 90.
    Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294–306.PubMedGoogle Scholar
  91. 91.
    Murphy SB, Hustu HO, Rivera G, Berard CW. End results of treating children with localized non-Hodgkin’s lymphomas with a combined modality approach of lessened intensity. J Clin Oncol. 1983;1(5):326–30.PubMedGoogle Scholar
  92. 92.
    Meadows AT, Sposto R, Jenkin RD, Kersey JH, Chilcote RR, Siegel SE, et al. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin’s lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol. 1989;7(1):92–9.PubMedGoogle Scholar
  93. 93.
    Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med. 1997;337(18):1259–66.PubMedCrossRefGoogle Scholar
  94. 94.
    Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, et al. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Adde M, Shad A, Venzon D, Arndt C, Gootenberg J, Neely J, et al. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol. 1998;25(2 Suppl 4):33–9; discussion 45–8.PubMedGoogle Scholar
  96. 96.
    Anderson JR, Jenkin RD, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol. 1993;11(6):1024–32.PubMedGoogle Scholar
  97. 97.
    Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925–34.PubMedGoogle Scholar
  98. 98.
    Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996;14(4):1252–61.PubMedGoogle Scholar
  99. 99.
    Dahl GV, Rivera G, Pui CH, Mirro Jr J, Ochs J, Kalwinsky DK, et al. A novel treatment of childhood lymphoblastic non-Hodgkin’s lymphoma: early and intermittent use of teniposide plus cytarabine. Blood. 1985;66(5):1110–4.PubMedGoogle Scholar
  100. 100.
    Santana VM, Abromowitch M, Sandlund JT, Behm FG, Ayers GD, Roberson PK, et al. MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin’s lymphoma. Leukemia. 1993;7(2):187–91.PubMedGoogle Scholar
  101. 101.
    Sandlund JT, Santana V, Abromowitch M, Ribeiro R, Mahmoud H, Ayers GD, et al. Large cell non-Hodgkin lymphoma of childhood: clinical characteristics and outcome. Leukemia. 1994;8(1):30–4.PubMedGoogle Scholar
  102. 102.
    Hutchison RE, Berard CW, Shuster JJ, Link MP, Pick TE, Murphy SB. B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol. 1995;13(8):2023–32.PubMedGoogle Scholar
  103. 103.
    Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood. 2011;118(4):874–83.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541–7.PubMedCrossRefGoogle Scholar
  105. 105.
    Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897–903.PubMedCrossRefGoogle Scholar
  106. 106.
    Tubergen DG, Krailo MD, Meadows AT, Rosenstock J, Kadin M, Morse M, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin’s lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995;13(6):1368–76.PubMedGoogle Scholar
  107. 107.
    Philip T, Hartmann O, Pinkerton R, Zucker JM, Gentet JC, Lamagnere JP, et al. Curability of relapsed childhood B-cell non-Hodgkin’s lymphoma after intensive first line therapy: a report from the Societe Francaise d’Oncologie Pediatrique. Blood. 1993;81(8):2003–6.PubMedGoogle Scholar
  108. 108.
    Gordon BG, Warkentin PI, Weisenburger DD, Vose JM, Sanger WG, Strandjord SE, et al. Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents. Blood. 1992;80(11):2938–42.PubMedGoogle Scholar
  109. 109.
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164–7.PubMedCrossRefGoogle Scholar
  110. 110.
    Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res. 2009;156(1):167–72.PubMedCrossRefGoogle Scholar
  111. 111.
    Haselkorn T, Bernstein L, Preston-Martin S, Cozen W, Mack WJ. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972-1995. Cancer Causes Control. 2000;11(2):163–70.PubMedCrossRefGoogle Scholar
  112. 112.
    Favus MJ, Schneider AB, Stachura ME, Arnold JE, Ryo UY, Pinsky SM, et al. Thyroid cancer occurring as a late consequence of head-and-neck irradiation. Evaluation of 1056 patients. N Engl J Med. 1976;294(19):1019–25.PubMedCrossRefGoogle Scholar
  113. 113.
    Linet MS, Kim KP, Rajaraman P. Children’s exposure to diagnostic medical radiation and cancer risk: epidemiologic and dosimetric considerations. Pediatr Radiol. 2009;39 Suppl 1:S4–26.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Rice HE, Frush DP, Farmer D, Waldhausen JH. Review of radiation risks from computed tomography: essentials for the pediatric surgeon. J Pediatr Surg. 2007;42(4):603–7.PubMedCrossRefGoogle Scholar
  115. 115.
    Mazonakis M, Tzedakis A, Damilakis J, Gourtsoyiannis N. Thyroid dose from common head and neck CT examinations in children: is there an excess risk for thyroid cancer induction? Eur Radiol. 2007;17(5):1352–7.PubMedCrossRefGoogle Scholar
  116. 116.
    Acharya S, Sarafoglou K, LaQuaglia M, Lindsley S, Gerald W, Wollner N, et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer. 2003;97(10):2397–403.PubMedCrossRefGoogle Scholar
  117. 117.
    Smith MB, Xue H, Strong L, Takahashi H, Jaffe N, Ried H, et al. Forty-year experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy. J Pediatr Surg. 1993;28(10):1342–8; discussion 8–9.PubMedCrossRefGoogle Scholar
  118. 118.
    Vane D, King DR, Boles Jr ET. Secondary thyroid neoplasms in pediatric cancer patients: increased risk with improved survival. J Pediatr Surg. 1984;19(6):855–60.PubMedCrossRefGoogle Scholar
  119. 119.
    Schlumberger M, De Vathaire F, Travagli JP, Vassal G, Lemerle J, Parmentier C, et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab. 1987;65(6):1088–94.PubMedCrossRefGoogle Scholar
  120. 120.
    Newman KD, Black T, Heller G, Azizkhan RG, Holcomb 3rd GW, Sklar C, et al. Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children’s Cancer Group. Ann Surg. 1998;227(4):533–41.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    La Quaglia MP, Corbally MT, Heller G, Exelby PR, Brennan MF. Recurrence and morbidity in differentiated thyroid carcinoma in children. Surgery. 1988;104(6):1149–56.PubMedGoogle Scholar
  122. 122.
    Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, et al. Subsequent malignancies in children treated for Hodgkin’s disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008;72(1):24–33.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Pacini F, Vorontsova T, Molinaro E, Shavrova E, Agate L, Kuchinskaya E, et al. Thyroid consequences of the Chernobyl nuclear accident. Acta Paediatr Suppl. 1999;88(433):23–7.PubMedCrossRefGoogle Scholar
  124. 124.
    Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster. Pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus. Cancer. 1994;74(2):748–66.PubMedCrossRefGoogle Scholar
  125. 125.
    Demidchik YE, Saenko VA, Yamashita S. Childhood thyroid cancer in Belarus, Russia, and Ukraine after Chernobyl and at present. Arq Bras Endocrinol Metabol. 2007;51(5):748–62.PubMedCrossRefGoogle Scholar
  126. 126.
    Stein L, Rothschild J, Luce J, Cowell JK, Thomas G, Bogdanova TI, et al. Copy number and gene expression alterations in radiation-induced papillary thyroid carcinoma from chernobyl pediatric patients. Thyroid. 2010;20(5):475–87.PubMedCrossRefGoogle Scholar
  127. 127.
    Hung W, Anderson KD, Chandra RS, Kapur SP, Patterson K, Randolph JG, et al. Solitary thyroid nodules in 71 children and adolescents. J Pediatr Surg. 1992;27(11):1407–9.PubMedCrossRefGoogle Scholar
  128. 128.
    Harness JK, Thompson NW, McLeod MK, Pasieka JL, Fukuuchi A. Differentiated thyroid carcinoma in children and adolescents. World J Surg. 1992;16(4):547–53; discussion 53–4.PubMedCrossRefGoogle Scholar
  129. 129.
    Santoro M, Thomas GA, Vecchio G, Williams GH, Fusco A, Chiappetta G, et al. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer. 2000;82(2):315–22.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab. 2000;85(3):1170–5.PubMedGoogle Scholar
  131. 131.
    Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res. 2000;6(3):1093–103.PubMedGoogle Scholar
  132. 132.
    Sozzi G, Bongarzone I, Miozzo M, Borrello MG, Blutti MG, Pilotti S, et al. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chromosomes Cancer. 1994;9(4):244–50.PubMedCrossRefGoogle Scholar
  133. 133.
    Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondellini P, et al. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res. 1994;54(11):2979–85.PubMedGoogle Scholar
  134. 134.
    Ory C, Ugolin N, Levalois C, Lacroix L, Caillou B, Bidart JM, et al. Gene expression signature discriminates sporadic from post-radiotherapy-induced thyroid tumors. Endocr Relat Cancer. 2011;18(1):193–206.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367(6461):375–6.PubMedCrossRefGoogle Scholar
  136. 136.
    Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells Jr SA. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg. 1996;31(1):177–81; discussion 81–2.PubMedCrossRefGoogle Scholar
  137. 137.
    Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 1994;3(2):237–41.PubMedCrossRefGoogle Scholar
  138. 138.
    Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, et al. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid. 2011;21(2):189–92.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Astl J, Dvorakova M, Vlcek P, Vesely D, Matucha P, Betka J. Thyroid surgery in children and adolescents. Int J Pediatr Otorhinolaryngol. 2004;68(10):1273–8.PubMedCrossRefGoogle Scholar
  140. 140.
    Samuel AM, Sharma SM. Differentiated thyroid carcinomas in children and adolescents. Cancer. 1991;67(8):2186–90.PubMedCrossRefGoogle Scholar
  141. 141.
    Zimmerman D, Hay ID, Gough IR, Goellner JR, Ryan JJ, Grant CS, et al. Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery. 1988;104(6):1157–66.PubMedGoogle Scholar
  142. 142.
    Vassilopoulou-Sellin R, Klein MJ, Smith TH, Samaan NA, Frankenthaler RA, Goepfert H, et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer. 1993;71(4):1348–52.PubMedCrossRefGoogle Scholar
  143. 143.
    Exelby PE, Frazell EL. Carcinoma of the thyroid in children. Surg Clin North Am. 1969;49(2):249–59.PubMedGoogle Scholar
  144. 144.
    Brauckhoff M, Machens A, Hess S, Lorenz K, Gimm O, Brauckhoff K, et al. Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery. 2008;144(6):1044–50; discussion 50–3.PubMedCrossRefGoogle Scholar
  145. 145.
    Wray CJ, Rich TA, Waguespack SG, Lee JE, Perrier ND, Evans DB. Failure to recognize multiple endocrine neoplasia 2B: more common than we think? Ann Surg Oncol. 2008;15(1):293–301.PubMedCrossRefGoogle Scholar
  146. 146.
    Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141(5):489–94; discussion 94–6.PubMedCrossRefGoogle Scholar
  147. 147.
    Yip FW, Reeve TS, Poole AG, Delbridge L. Thyroid nodules in childhood and adolescence. Aust N Z J Surg. 1994;64(10):676–8.PubMedCrossRefGoogle Scholar
  148. 148.
    Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91(11):4295–301.PubMedCrossRefGoogle Scholar
  149. 149.
    Corrias A, Einaudi S, Chiorboli E, Weber G, Crino A, Andreo M, et al. Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. J Clin Endocrinol Metab. 2001;86(10):4644–8.PubMedCrossRefGoogle Scholar
  150. 150.
    Hung W. Solitary thyroid nodules in 93 children and adolescents: a 35-years experience. Horm Res. 1999;52(1):15–8.PubMedCrossRefGoogle Scholar
  151. 151.
    Gharib H, Zimmerman D, Goellner JR, Bridley SM, LeBlanc SM. Fine-needle aspiration biopsy: use in diagnosis and management of pediatric thyroid diseases. Endocr Pract. 1995;1(1):9–13.PubMedCrossRefGoogle Scholar
  152. 152.
    Edge SB, Byrd DR, Compton CC. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  153. 153.
    Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.PubMedCrossRefGoogle Scholar
  154. 154.
    Ceccarelli C, Pacini F, Lippi F, Pinchera A. An unusual case of a false-positive iodine-131 whole body scan in a patient with papillary thyroid cancer. Clin Nucl Med. 1988;13(3):192–3.PubMedCrossRefGoogle Scholar
  155. 155.
    de Roy van Zuidewijn DB, Songun I, Kievit J, van de Velde CJ. Complications of thyroid surgery. Ann Surg Oncol. 1995;2(1):56–60.CrossRefGoogle Scholar
  156. 156.
    Brauckhoff M, Gimm O, Thanh PN, Brauckhoff K, Ukkat J, Thomusch O, et al. First experiences in intraoperative neurostimulation of the recurrent laryngeal nerve during thyroid surgery of children and adolescents. J Pediatr Surg. 2002;37(10):1414–8.PubMedCrossRefGoogle Scholar
  157. 157.
    Wells Jr SA, Farndon JR, Dale JK, Leight GS, Dilley WG. Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg. 1980;192(4):451–8.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Skinner MA, Norton JA, Moley JF, DeBenedetti MK, Wells Jr SA. Heterotopic autotransplantation of parathyroid tissue in children undergoing total thyroidectomy. J Pediatr Surg. 1997;32(3):510–3.PubMedCrossRefGoogle Scholar
  159. 159.
    Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery. 2003;133(2):180–5.PubMedCrossRefGoogle Scholar
  160. 160.
    Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg. 2010;34(6):1192–202.PubMedCrossRefGoogle Scholar
  161. 161.
    Scholz S, Smith JR, Chaignaud B, Shamberger RC, Huang SA. Thyroid surgery at Children’s Hospital Boston: a 35-year single-institution experience. J Pediatr Surg. 2011;46(3):437–42.PubMedCrossRefGoogle Scholar
  162. 162.
    Kirk JM, Mort C, Grant DB, Touzel RJ, Plowman N. The usefulness of serum thyroglobulin in the follow-up of differentiated thyroid carcinoma in children. Med Pediatr Oncol. 1992;20(3):201–8.PubMedCrossRefGoogle Scholar
  163. 163.
    Gorlin JB, Sallan SE. Thyroid cancer in childhood. Endocrinol Metab Clin North Am. 1990;19(3):649–62.PubMedGoogle Scholar
  164. 164.
    Wells Jr SA, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 1994;220(3):237–47; discussion 47–50.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells Jr SA. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353(11):1105–13.PubMedCrossRefGoogle Scholar
  166. 166.
    Norton JA, Froome LC, Farrell RE, Wells Jr SA. Multiple endocrine neoplasia type IIb: the most aggressive form of medullary thyroid carcinoma. Surg Clin North Am. 1979;59(1):109–18.PubMedGoogle Scholar
  167. 167.
    Howe JR, Norton JA, Wells Jr SA. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery. 1993;114(6):1070–7.PubMedGoogle Scholar
  168. 168.
    Vaisman F, Bulzico DA, Pessoa CH, Bordallo MA, Mendonca UB, Dias FL, et al. Prognostic factors of a good response to initial therapy in children and adolescents with differentiated thyroid cancer. Clinics (Sao Paulo). 2011;66(2):281–6.CrossRefGoogle Scholar
  169. 169.
    Rohmer V, Vidal-Trecan G, Bourdelot A, Niccoli P, Murat A, Wemeau JL, et al. Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d’Etude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2011;96(3):E509–18.PubMedCrossRefGoogle Scholar
  170. 170.
    Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117(19):4439–46.PubMedPubMedCentralCrossRefGoogle Scholar
  171. 171.
    Fallahi B, Adabi K, Majidi M, Fard-Esfahani A, Heshmat R, Larijani B, et al. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clin Nucl Med. 2011;36(4):277–82.PubMedCrossRefGoogle Scholar
  172. 172.
    Brodeur G, Maris J. In: Pizzo P, Poplack D, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins; 2002.Google Scholar
  173. 173.
    Goodman M, Gurney J, Smith M, Olshan A. Sympathetic nervous system tumors. In: Ries L, Smith M, Gurney J, et al., editors. Bethesda: National Cancer Institute; 1999.Google Scholar
  174. 174.
    Young Jr JL, Ries LG, Silverberg E, Horm JW, Miller RW. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer. 1986;58(2 Suppl):598–602.PubMedCrossRefGoogle Scholar
  175. 175.
    Brown RJ, Szymula NJ, Lore Jr JM. Neuroblastoma of the head and neck. Arch Otolaryngol. 1978;104(7):395–8.PubMedCrossRefGoogle Scholar
  176. 176.
    French AE, Grant R, Weitzman S, Ray JG, Vermeulen MJ, Sung L, et al. Folic acid food fortification is associated with a decline in neuroblastoma. Clin Pharmacol Ther. 2003;74(3):288–94.PubMedCrossRefGoogle Scholar
  177. 177.
    Cook MN, Olshan AF, Guess HA, Savitz DA, Poole C, Blatt J, et al. Maternal medication use and neuroblastoma in offspring. Am J Epidemiol. 2004;159(8):721–31.PubMedCrossRefGoogle Scholar
  178. 178.
    Blatt J, Olshan AF, Lee PA, Ross JL. Neuroblastoma and related tumors in Turner’s syndrome. J Pediatr. 1997;131(5):666–70.PubMedCrossRefGoogle Scholar
  179. 179.
    Nemecek ER, Sawin RW, Park J. Treatment of neuroblastoma in patients with neurocristopathy syndromes. J Pediatr Hematol Oncol. 2003;25(2):159–62.PubMedCrossRefGoogle Scholar
  180. 180.
    Maris JM, Chatten J, Meadows AT, Biegel JA, Brodeur GM. Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease. Med Pediatr Oncol. 1997;28(1):1–5.PubMedCrossRefGoogle Scholar
  181. 181.
    Kushner BH, Hajdu SI, Helson L. Synchronous neuroblastoma and von Recklinghausen’s disease: a review of the literature. J Clin Oncol. 1985;3(1):117–20.PubMedGoogle Scholar
  182. 182.
    Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer. 1986;57(9):1887–93.PubMedCrossRefGoogle Scholar
  183. 183.
    Roberts T, Chernova O, Cowell JK. NB4S, a member of the TBC1 domain family of genes, is truncated as a result of a constitutional t(1;10)(p22;q21) chromosome translocation in a patient with stage 4S neuroblastoma. Hum Mol Genet. 1998;7(7):1169–78.PubMedCrossRefGoogle Scholar
  184. 184.
    Krona C, Ejeskar K, Abel F, Kogner P, Bjelke J, Bjork E, et al. Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene. 2003;22(15):2343–51.PubMedCrossRefGoogle Scholar
  185. 185.
    Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children’s Cancer Group study. J Clin Oncol. 2000;18(9):1888–99.PubMedGoogle Scholar
  186. 186.
    Biegel JA, White PS, Marshall HN, Fujimori M, Zackai EH, Scher CD, et al. Constitutional 1p36 deletion in a child with neuroblastoma. Am J Hum Genet. 1993;52(1):176–82.PubMedPubMedCentralGoogle Scholar
  187. 187.
    White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M, et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A. 1995;92(12):5520–4.PubMedPubMedCentralCrossRefGoogle Scholar
  188. 188.
    Mead RS, Cowell JK. Molecular characterization of a (1;10)(p22;q21) constitutional translocation from a patient with neuroblastoma. Cancer Genet Cytogenet. 1995;81(2):151–7.PubMedCrossRefGoogle Scholar
  189. 189.
    Komuro H, Valentine MB, Rowe ST, Kidd VJ, Makino S, Brodeur GM, et al. Fluorescence in situ hybridization analysis of chromosome 1p36 deletions in human MYCN amplified neuroblastoma. J Pediatr Surg. 1998;33(11):1695–8.PubMedCrossRefGoogle Scholar
  190. 190.
    Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE, et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A. 1989;86(10):3753–7.PubMedPubMedCentralCrossRefGoogle Scholar
  191. 191.
    Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson AD, Plantaz D, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340(25):1954–61.PubMedCrossRefGoogle Scholar
  192. 192.
    Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol. 2005;23(10):2280–99.PubMedCrossRefGoogle Scholar
  193. 193.
    Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353(21):2243–53.PubMedCrossRefGoogle Scholar
  194. 194.
    Srivatsan ES, Ying KL, Seeger RC. Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosomes Cancer. 1993;7(1):32–7.PubMedCrossRefGoogle Scholar
  195. 195.
    Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121–4.PubMedCrossRefGoogle Scholar
  196. 196.
    Brodeur GM, Azar C, Brother M, Hiemstra J, Kaufman B, Marshall H, et al. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer. 1992;70(6 Suppl):1685–94.PubMedCrossRefGoogle Scholar
  197. 197.
    Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9(4):581–91.PubMedGoogle Scholar
  198. 198.
    Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res. 1993;53(9):2044–50.PubMedGoogle Scholar
  199. 199.
    Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst. 1993;85(5):377–84.PubMedCrossRefGoogle Scholar
  200. 200.
    Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 1992;52(5):1364–8.PubMedGoogle Scholar
  201. 201.
    Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993;328(12):847–54.PubMedCrossRefGoogle Scholar
  202. 202.
    Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984;311(4):231–5.PubMedCrossRefGoogle Scholar
  203. 203.
    Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst. 1997;89(5):373–80.PubMedCrossRefGoogle Scholar
  204. 204.
    Woodruff G, Buncic JR, Morin JD. Horner’s syndrome in children. J Pediatr Ophthalmol Strabismus. 1988;25(1):40–4.PubMedGoogle Scholar
  205. 205.
    Ogita S, Tokiwa K, Takahashi T, Imashuku S, Sawada T. Congenital cervical neuroblastoma associated with Horner syndrome. J Pediatr Surg. 1988;23(11):991–2.PubMedCrossRefGoogle Scholar
  206. 206.
    George ND, Gonzalez G, Hoyt CS. Does Horner’s syndrome in infancy require investigation? Br J Ophthalmol. 1998;82(1):51–4.PubMedPubMedCentralCrossRefGoogle Scholar
  207. 207.
    Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466–77.PubMedGoogle Scholar
  208. 208.
    Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289–97.PubMedPubMedCentralCrossRefGoogle Scholar
  209. 209.
    Available from: 24 June 2012.
  210. 210.
    Nitschke R, Smith EI, Shochat S, Altshuler G, Travers H, Shuster JJ, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol. 1988;6(8):1271–9.PubMedGoogle Scholar
  211. 211.
    Evans AE, Silber JH, Shpilsky A, D’Angio GJ. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol. 1996;14(9):2504–10.PubMedGoogle Scholar
  212. 212.
    Kushner BH, Cheung NK, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla MA, et al. International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. J Clin Oncol. 1996;14(7):2174–80.PubMedGoogle Scholar
  213. 213.
    Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children’s cancer group study. J Clin Oncol. 2000;18(1):18–26.PubMedGoogle Scholar
  214. 214.
    Alvarado CS, London WB, Look AT, Brodeur GM, Altmiller DH, Thorner PS, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2000;22(3):197–205.PubMedCrossRefGoogle Scholar
  215. 215.
    Davidoff AM. Neuroblastoma. Semin Pediatr Surg. 2012;21(1):2–14.PubMedPubMedCentralCrossRefGoogle Scholar
  216. 216.
    Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol. 1998;16(4):1256–64.PubMedGoogle Scholar
  217. 217.
    Strother D, van Hoff J, Rao PV, Smith EI, Shamberger RC, Halperin EC, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer. 1997;33(12):2121–5.PubMedCrossRefGoogle Scholar
  218. 218.
    Green AA, Hayes FA, Hustu HO. Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma. Cancer. 1981;48(10):2310–7.PubMedCrossRefGoogle Scholar
  219. 219.
    Garaventa A, De Bernardi B, Pianca C, Donfrancesco A, Cordero di Montezemolo L, Di Tullio MT, et al. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma. J Clin Oncol. 1993;11(9):1770–9.PubMedGoogle Scholar
  220. 220.
    Nitschke R, Smith EI, Altshuler G, Altmiller D, Shuster J, Green A, et al. Postoperative treatment of nonmetastatic visible residual neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9(7):1181–8.PubMedGoogle Scholar
  221. 221.
    DeCou JM, Bowman LC, Rao BN, Santana VM, Furman WL, Luo X, et al. Infants with metastatic neuroblastoma have improved survival with resection of the primary tumor. J Pediatr Surg. 1995;30(7):937–40; discussion 40–1.PubMedCrossRefGoogle Scholar
  222. 222.
    Jacobson HM, Marcus Jr RB, Thar TL, Million RR, Graham-Pole JR, Talbert JL. Pediatric neuroblastoma: postoperative radiation therapy using less than 2000 rad. Int J Radiat Oncol Biol Phys. 1983;9(4):501–5.PubMedCrossRefGoogle Scholar
  223. 223.
    Castleberry RP, Kun LE, Shuster JJ, Altshuler G, Smith IE, Nitschke R, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol. 1991;9(5):789–95.PubMedGoogle Scholar
  224. 224.
    Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children’s Cancer Study Group investigation. J Clin Oncol. 1992;10(12):1889–96.PubMedGoogle Scholar
  225. 225.
    Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer. 2011;117(18):4286–93.PubMedPubMedCentralCrossRefGoogle Scholar
  226. 226.
    Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341(16):1165–73.PubMedCrossRefGoogle Scholar
  227. 227.
    Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008;55(1):97–120, x.PubMedCrossRefGoogle Scholar
  228. 228.
    Castleberry RP, Cantor AB, Green AA, Joshi V, Berkow RL, Buchanan GR, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1994;12(8):1616–20.PubMedGoogle Scholar
  229. 229.
    Hartmann O, Pinkerton CR, Philip T, Zucker JM, Breatnach F. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol. 1988;6(1):44–50.PubMedGoogle Scholar
  230. 230.
    Haase GM, Wong KY, deLorimier AA, Sather HN, Hammond GD. Improvement in survival after excision of primary tumor in stage III neuroblastoma. J Pediatr Surg. 1989;24(2):194–200.PubMedCrossRefGoogle Scholar
  231. 231.
    Philip T, Zucker JM, Bernard JL, Lutz P, Bordigoni P, Plouvier E, et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol. 1991;9(6):1037–44.PubMedGoogle Scholar
  232. 232.
    Kramer S, Meadows AT, Jarrett P, Evans AE. Incidence of childhood cancer: experience of a decade in a population-based registry. J Natl Cancer Inst. 1983;70(1):49–55.PubMedGoogle Scholar
  233. 233.
    Ries L, Smith M, Gurney J, et al. editors. Cancer incidence and survival among children and adolescents. United States SEER Program. National Cancer Institute, SEER Program, NIH; 1999.Google Scholar
  234. 234.
    Stiller CA, Parkin DM. International variations in the incidence of childhood soft-tissue sarcomas. Paediatr Perinat Epidemiol. 1994;8(1):107–19.PubMedCrossRefGoogle Scholar
  235. 235.
    Parkin DM, Stiller CA, Draper GJ, Bieber CA. The international incidence of childhood cancer. Int J Cancer. 1988;42(4):511–20.PubMedCrossRefGoogle Scholar
  236. 236.
    Stiller CA, McKinney PA, Bunch KJ, Bailey CC, Lewis IJ. Childhood cancer and ethnic group in Britain: a United Kingdom children’s Cancer Study Group (UKCCSG) study. Br J Cancer. 1991;64(3):543–8.PubMedPubMedCentralCrossRefGoogle Scholar
  237. 237.
    McGill T. Rhabdomyosarcoma of the head and neck: an update. Otolaryngol Clin North Am. 1989;22(3):631–6.PubMedGoogle Scholar
  238. 238.
    Hartley AL, Birch JM, Marsden HB, Harris M, Blair V. Neurofibromatosis in children with soft tissue sarcoma. Pediatr Hematol Oncol. 1988;5(1):7–16.PubMedCrossRefGoogle Scholar
  239. 239.
    Smith AC, Squire JA, Thorner P, Zielenska M, Shuman C, Grant R, et al. Association of alveolar rhabdomyosarcoma with the Beckwith-Wiedemann syndrome. Pediatr Dev Pathol. 2001;4(6):550–8.PubMedCrossRefGoogle Scholar
  240. 240.
    Gripp KW, Scott Jr CI, Nicholson L, McDonald-McGinn DM, Ozeran JD, Jones MC, et al. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet. 2002;108(1):80–7.PubMedCrossRefGoogle Scholar
  241. 241.
    Hennekam RC. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet. 2003;117(1):42–8.CrossRefGoogle Scholar
  242. 242.
    Matsui I, Tanimura M, Kobayashi N, Sawada T, Nagahara N, Akatsuka J. Neurofibromatosis type 1 and childhood cancer. Cancer. 1993;72(9):2746–54.PubMedCrossRefGoogle Scholar
  243. 243.
    DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr. 1998;132(3 Pt 1):398–400.PubMedCrossRefGoogle Scholar
  244. 244.
    Li FP, Fraumeni Jr JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71(4):747–52.PubMedCrossRefGoogle Scholar
  245. 245.
    Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist. 1999;4(1):34–44.PubMedGoogle Scholar
  246. 246.
    Hartley AL, Birch JM, McKinney PA, Blair V, Teare MD, Carrette J, et al. The Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): past medical history in children with cancer. J Epidemiol Community Health. 1988;42(3):235–42.PubMedPubMedCentralCrossRefGoogle Scholar
  247. 247.
    Magnani C, Pastore G, Luzzatto L, Carli M, Lubrano P, Terracini B. Risk factors for soft tissue sarcomas in childhood: a case-control study. Tumori. 1989;75(4):396–400.PubMedGoogle Scholar
  248. 248.
    Grufferman S, Schwartz AG, Ruymann FB, Maurer HM. Parents’ use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control. 1993;4(3):217–24.PubMedGoogle Scholar
  249. 249.
    Grufferman S, Gula M, Olshan A, et al. In utero X-ray exposure and risk of childhood rhabdomyosarcoma. Paediatr Perinat Epidemiol. 1991;5:A6.Google Scholar
  250. 250.
    Hartley AL, Birch JM, Blair V, Kelsey AM, Harris M, Jones PH. Patterns of cancer in the families of children with soft tissue sarcoma. Cancer. 1993;72(3):923–30.PubMedCrossRefGoogle Scholar
  251. 251.
    Birch JM, Hartley AL, Blair V, Kelsey AM, Harris M, Teare MD, et al. Cancer in the families of children with soft tissue sarcoma. Cancer. 1990;66(10):2239–48.PubMedCrossRefGoogle Scholar
  252. 252.
    Li FP, Fraumeni Jr JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48(18):5358–62.PubMedGoogle Scholar
  253. 253.
    Parham DM, Webber B, Holt H, Williams WK, Maurer H. Immunohistochemical study of childhood rhabdomyosarcomas and related neoplasms. Results of an Intergroup Rhabdomyosarcoma study project. Cancer. 1991;67(12):3072–80.PubMedCrossRefGoogle Scholar
  254. 254.
    Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S, et al. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol. 2000;156(2):399–408.PubMedPubMedCentralCrossRefGoogle Scholar
  255. 255.
    Dias P, Parham DM, Shapiro DN, Webber BL, Houghton PJ. Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol. 1990;137(6):1283–91.PubMedPubMedCentralGoogle Scholar
  256. 256.
    Scrable H, Witte D, Shimada H, Seemayer T, Sheng WW, Soukup S, et al. Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer. 1989;1(1):23–35.PubMedCrossRefGoogle Scholar
  257. 257.
    Halliday BE, Slagel DD, Elsheikh TE, Silverman JF. Diagnostic utility of MIC-2 immunocytochemical staining in the differential diagnosis of small blue cell tumors. Diagn Cytopathol. 1998;19(6):410–6.PubMedCrossRefGoogle Scholar
  258. 258.
    Kodet R, Newton Jr WA, Hamoudi AB, Asmar L, Jacobs DL, Maurer HM. Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features. A report of the Intergroup Rhabdomyosarcoma Study. Am J Surg Pathol. 1993;17(5):443–53.PubMedCrossRefGoogle Scholar
  259. 259.
    Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–30.PubMedCrossRefGoogle Scholar
  260. 260.
    Hostein I, Andraud-Fregeville M, Guillou L, Terrier-Lacombe MJ, Deminiere C, Ranchere D, et al. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer. 2004;101(12):2817–24.PubMedCrossRefGoogle Scholar
  261. 261.
    Tsokos M. The diagnosis and classification of childhood rhabdomyosarcoma. Semin Diagn Pathol. 1994;11(1):26–38.PubMedGoogle Scholar
  262. 262.
    Tsokos M, Webber BL, Parham DM, Wesley RA, Miser A, Miser JS, et al. Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med. 1992;116(8):847–55.PubMedGoogle Scholar
  263. 263.
    Feinberg AP. Genomic imprinting and gene activation in cancer. Nat Genet. 1993;4(2):110–3.PubMedCrossRefGoogle Scholar
  264. 264.
    Scrable HJ, Witte DP, Lampkin BC, Cavenee WK. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature. 1987;329(6140):645–7.PubMedCrossRefGoogle Scholar
  265. 265.
    El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ. 1990;1(7):325–31.PubMedGoogle Scholar
  266. 266.
    Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A. 1999;96(23):13264–9.PubMedPubMedCentralCrossRefGoogle Scholar
  267. 267.
    Stratton MR, Fisher C, Gusterson BA, Cooper CS. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1989;49(22):6324–7.PubMedGoogle Scholar
  268. 268.
    Anderson J, Gordon A, Pritchard-Jones K, Shipley J. Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer. 1999;26(4):275–85.PubMedCrossRefGoogle Scholar
  269. 269.
    Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G, Zhang J, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002;33(3):310–21.PubMedCrossRefGoogle Scholar
  270. 270.
    Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther. 2002;1(2):97–104.PubMedCrossRefGoogle Scholar
  271. 271.
    Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992;52(8):2243–7.PubMedGoogle Scholar
  272. 272.
    Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010;70(16):6497–508.PubMedPubMedCentralCrossRefGoogle Scholar
  273. 273.
    Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, et al. Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children’s Oncology Group. Am J Pathol. 2009;174(2):550–64.PubMedPubMedCentralCrossRefGoogle Scholar
  274. 274.
    Davis RJ, D’Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994;54(11):2869–72.PubMedGoogle Scholar
  275. 275.
    Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher 3rd FJ, Emanuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;5(3):230–5.PubMedCrossRefGoogle Scholar
  276. 276.
    Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res. 1993;53(21):5108–12.PubMedGoogle Scholar
  277. 277.
    Raney Jr RB, Tefft M, Maurer HM, Ragab AH, Hays DM, Soule EH, et al. Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I. Cancer. 1988;62(7):1257–66.PubMedCrossRefGoogle Scholar
  278. 278.
    Kelly KM, Womer RB, Sorensen PH, Xiong QB, Barr FG. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol. 1997;15(5):1831–6.PubMedGoogle Scholar
  279. 279.
    Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;71(5):1904–22.PubMedCrossRefGoogle Scholar
  280. 280.
    Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988;61(2):209–20.PubMedCrossRefGoogle Scholar
  281. 281.
    Months SR, Raney RB. Rhabdomyosarcoma of the head and neck in children: the experience at the Children’s Hospital of Philadelphia. Med Pediatr Oncol. 1986;14(5):288–92.PubMedCrossRefGoogle Scholar
  282. 282.
    Koscielniak E, Rodary C, Flamant F, Carli M, Treuner J, Pinkerton CR, et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med Pediatr Oncol. 1992;20(3):209–14.PubMedCrossRefGoogle Scholar
  283. 283.
    Hicks J, Flaitz C. Rhabdomyosarcoma of the head and neck in children. Oral Oncol. 2002;38(5):450–9.PubMedCrossRefGoogle Scholar
  284. 284.
    Lawrence Jr W, Hays DM, Heyn R, Tefft M, Crist W, Beltangady M, et al. Lymphatic metastases with childhood rhabdomyosarcoma. A report from the Intergroup Rhabdomyosarcoma Study. Cancer. 1987;60(4):910–5.PubMedCrossRefGoogle Scholar
  285. 285.
    Kumar R, Shandal V, Shamim SA, Halanaik D, Malhotra A. Clinical applications of PET and PET/CT in pediatric malignancies. Expert Rev Anticancer Ther. 2010;10(5):755–68.PubMedCrossRefGoogle Scholar
  286. 286.
    Mody RJ, Bui C, Hutchinson RJ, Yanik GA, Castle VP, Frey KA, et al. FDG PET imaging of childhood sarcomas. Pediatr Blood Cancer. 2010;54(2):222–7.PubMedPubMedCentralGoogle Scholar
  287. 287.
    Tateishi U, Hosono A, Makimoto A, Nakamoto Y, Kaneta T, Fukuda H, et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med. 2009;23(2):155–61.PubMedCrossRefGoogle Scholar
  288. 288.
    Lawrence Jr W, Gehan EA, Hays DM, Beltangady M, Maurer HM. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol. 1987;5(1):46–54.PubMedGoogle Scholar
  289. 289.
    Lawrence Jr W, Anderson JR, Gehan EA, Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children’s Cancer Study Group. Pediatric Oncology Group. Cancer. 1997;80(6):1165–70.PubMedCrossRefGoogle Scholar
  290. 290.
    Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2003;21(1):78–84.PubMedCrossRefGoogle Scholar
  291. 291.
    Kayton ML, Delgado R, Busam K, Cody 3rd HS, Athanasian EA, Coit D, et al. Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients. Cancer. 2008;112(9):2052–9.PubMedCrossRefGoogle Scholar
  292. 292.
    Gow KW, Rapkin LB, Olson TA, Durham MM, Wyly B, Shehata BM. Sentinel lymph node biopsy in the pediatric population. J Pediatr Surg. 2008;43(12):2193–8.PubMedCrossRefGoogle Scholar
  293. 293.
    De Corti F, Dall’Igna P, Bisogno G, Casara D, Rossi CR, Foletto M, et al. Sentinel node biopsy in pediatric soft tissue sarcomas of extremities. Pediatr Blood Cancer. 2009;52(1):51–4.PubMedCrossRefGoogle Scholar
  294. 294.
    Temeck BK, Wexler LH, Steinberg SM, McClure LL, Horowitz M, Pass HI. Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg. 1995;59(6):1385–9; discussion 90.PubMedCrossRefGoogle Scholar
  295. 295.
    Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13(3):610–30.PubMedGoogle Scholar
  296. 296.
    Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19(12):3091–102.PubMedGoogle Scholar
  297. 297.
    Pappo AS, Lyden E, Breneman J, Wiener E, Teot L, Meza J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J Clin Oncol. 2001;19(1):213–9.PubMedGoogle Scholar
  298. 298.
    Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children’s Oncology Group study. J Clin Oncol. 2004;22(8):1398–403.PubMedCrossRefGoogle Scholar
  299. 299.
    Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 1999;17(6):1815–24.PubMedGoogle Scholar
  300. 300.
    Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Lobe T, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol. 2001;23(4):225–33.PubMedCrossRefGoogle Scholar
  301. 301.
    Sandler E, Lyden E, Ruymann F, Maurer H, Wharam M, Parham D, et al. Efficacy of ifosfamide and doxorubicin given as a phase II “window” in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol. 2001;37(5):442–8.PubMedCrossRefGoogle Scholar
  302. 302.
    Michalski JM, Meza J, Breneman JC, Wolden SL, Laurie F, Jodoin M, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys. 2004;59(4):1027–38.PubMedCrossRefGoogle Scholar
  303. 303.
    Smith LM, Anderson JR, Qualman SJ, Crist WM, Paidas CN, Teot LA, et al. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children’s oncology group. J Clin Oncol. 2001;19(20):4058–64.PubMedGoogle Scholar
  304. 304.
    Meazza C, Ferrari A, Casanova M, Gandola L, Collini P, Massimino M, et al. Evolving treatment strategies for parameningeal rhabdomyosarcoma: the experience of the Istituto Nazionale Tumori of Milan. Head Neck. 2005;27(1):49–57.PubMedCrossRefGoogle Scholar
  305. 305.
    Raney RB, Meza J, Anderson JR, Fryer CJ, Donaldson SS, Breneman JC, et al. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol. 2002;38(1):22–32.PubMedCrossRefGoogle Scholar
  306. 306.
    Raney B, Anderson J, Breneman J, Donaldson SS, Huh W, Maurer H, et al. Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008;51(1):17–22.PubMedCrossRefGoogle Scholar
  307. 307.
    Defachelles AS, Rey A, Oberlin O, Spooner D, Stevens MC. Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: results from international society of pediatric oncology studies MMT 89 and 95. J Clin Oncol. 2009;27(8):1310–5.PubMedCrossRefGoogle Scholar
  308. 308.
    Combs SE, Behnisch W, Kulozik AE, Huber PE, Debus J, Schulz-Ertner D. Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma. BMC Cancer. 2007;7:177.PubMedPubMedCentralCrossRefGoogle Scholar
  309. 309.
    McDonald MW, Esiashvili N, George BA, Katzenstein HM, Olson TA, Rapkin LB, et al. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2008;72(3):884–91.PubMedCrossRefGoogle Scholar
  310. 310.
    Curtis AE, Okcu MF, Chintagumpala M, Teh BS, Paulino AC. Local control after intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2009;73(1):173–7.PubMedCrossRefGoogle Scholar
  311. 311.
    Koscielniak E, Klingebiel TH, Peters C, Hermann J, Burdach ST, Bender-Gotze C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant. 1997;19(3):227–31.PubMedCrossRefGoogle Scholar
  312. 312.
    Antman K, Crowley J, Balcerzak SP, Kempf RA, Weiss RB, Clamon GH, et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing’s sarcoma, and rhabdomyosarcoma. Cancer. 1998;82(7):1288–95.PubMedCrossRefGoogle Scholar
  313. 313.
    Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987;5(8):1191–8.PubMedGoogle Scholar
  314. 314.
    Carpenter PA, White L, McCowage GB, Nayanar V, Toogood I, Shaw PJ, et al. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children’s Cancer Study Group. Cancer. 1997;80(3):489–96.PubMedCrossRefGoogle Scholar
  315. 315.
    Walterhouse DO, Hoover ML, Marymont MA, Kletzel M. High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children’s Memorial Hospital. Med Pediatr Oncol. 1999;32(2):88–92.PubMedCrossRefGoogle Scholar
  316. 316.
    Boulad F, Kernan NA, LaQuaglia MP, Heller G, Lindsley KL, Rosenfield NS, et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing’s sarcoma, and undifferentiated sarcoma. J Clin Oncol. 1998;16(5):1697–706.PubMedGoogle Scholar
  317. 317.
    Miser JS, Pizzo PA. Soft tissue sarcomas in childhood. Pediatr Clin North Am. 1985;32(3):779–800.PubMedGoogle Scholar
  318. 318.
    Chabalko JJ, Creagan ET, Fraumeni Jr JF. Epidemiology of selected sarcomas in children. J Natl Cancer Inst. 1974;53(3):675–9.PubMedGoogle Scholar
  319. 319.
    Raney B, Schnaufer L, Ziegler M, Chatten J, Littman P, Jarrett P. Treatment of children with neurogenic sarcoma. Experience at the Children’s Hospital of Philadelphia, 1958-1984. Cancer. 1987;59(1):1–5.PubMedCrossRefGoogle Scholar
  320. 320.
    Soule EH, Pritchard DJ. Fibrosarcoma in infants and children: a review of 110 cases. Cancer. 1977;40(4):1711–21.PubMedCrossRefGoogle Scholar
  321. 321.
    Chung EB, Enzinger FM. Infantile fibrosarcoma. Cancer. 1976;38(2):729–39.PubMedCrossRefGoogle Scholar
  322. 322.
    Neville H, Corpron C, Blakely ML, Andrassy R. Pediatric neurofibrosarcoma. J Pediatr Surg. 2003;38(3):343–6; discussion 343−6.PubMedCrossRefGoogle Scholar
  323. 323.
    Glover TW, Stein CK, Legius E, Andersen LB, Brereton A, Johnson S. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosomes Cancer. 1991;3(1):62–70.PubMedCrossRefGoogle Scholar
  324. 324.
    Demir HA, Varan A, Yalcn B, Akyuz C, Kutluk T, Buyukpamukcu M. Malignant peripheral nerve sheath tumors in childhood: 13 cases from a single center. J Pediatr Hematol Oncol. 2012;34(3):204–7.PubMedCrossRefGoogle Scholar
  325. 325.
    Bukachevsky RP, Pincus RL, Shechtman FG, Sarti E, Chodosh P. Synovial sarcoma of the head and neck. Head Neck. 1992;14(1):44–8.PubMedCrossRefGoogle Scholar
  326. 326.
    Moore DM, Berke GS. Synovial sarcoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1987;113(3):311–3.PubMedCrossRefGoogle Scholar
  327. 327.
    Albritton KH. Sarcomas in adolescents and young adults. Hematol Oncol Clin North Am. 2005;19(3):527–46, vii.PubMedCrossRefGoogle Scholar
  328. 328.
    Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73(10):2506–11.PubMedCrossRefGoogle Scholar
  329. 329.
    Raney R. Proceedings of the tumor board of The Children’s Hospital of Philadelphia: synovial sarcoma. Med Pediatr Oncol. 1981;9(1):41–5.CrossRefGoogle Scholar
  330. 330.
    Harb WJ, Luna MA, Patel SR, Ballo MT, Roberts DB, Sturgis EM. Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck. 2007;29(8):731–40.PubMedCrossRefGoogle Scholar
  331. 331.
    Koscielny S, Brauer B, Forster G. Hemangiopericytoma: a rare head and neck tumor. Eur Arch Otorhinolaryngol. 2003;260(8):450–3.PubMedCrossRefGoogle Scholar
  332. 332.
    Ordonez NG, Mackay B, el-Naggar AK, Byers RM. Congenital hemangiopericytoma. An ultrastructural, immunocytochemical, and flow cytometric study. Arch Pathol Lab Med. 1993;117(9):934–7.PubMedGoogle Scholar
  333. 333.
    Sreekantaiah C, Bridge JA, Rao UN, Neff JR, Sandberg AA. Clonal chromosomal abnormalities in hemangiopericytoma. Cancer Genet Cytogenet. 1991;54(2):173–81.PubMedCrossRefGoogle Scholar
  334. 334.
    Auguste LJ, Razack MS, Sako K. Hemangiopericytoma. J Surg Oncol. 1982;20(4):260–4.PubMedCrossRefGoogle Scholar
  335. 335.
    Backwinkel KD, Diddams JA. Hemangiopericytoma. Report of a case and comprehensive review of the literature. Cancer. 1970;25(4):896–901.PubMedCrossRefGoogle Scholar
  336. 336.
    Rydholm A, Mandahl N, Heim S, Kreicbergs A, Willen H, Mitelman F. Malignant fibrous histiocytomas with a 19p+ marker chromosome have increased relapse rate. Genes Chromosomes Cancer. 1990;2(4):296–9.PubMedCrossRefGoogle Scholar
  337. 337.
    Mandahl N, Heim S, Willen H, Rydholm A, Eneroth M, Nilbert M, et al. Characteristic karyotypic anomalies identify subtypes of malignant fibrous histiocytoma. Genes Chromosomes Cancer. 1989;1(1):9–14.PubMedCrossRefGoogle Scholar
  338. 338.
    Shinjo K. Analysis of prognostic factors and chemotherapy of malignant fibrous histiocytoma of soft tissue: a preliminary report. Jpn J Clin Oncol. 1994;24(3):154–9.PubMedGoogle Scholar
  339. 339.
    Clamon GH, Robinson RA, Olberding EB. Prolonged remission of metastatic malignant fibrous histiocytoma induced by combination chemotherapy. J Surg Oncol. 1984;26(2):113–4.PubMedCrossRefGoogle Scholar
  340. 340.
    Raney Jr RB, Allen A, O’Neill J, Handler SD, Uri A, Littman P. Malignant fibrous histiocytoma of soft tissue in childhood. Cancer. 1986;57(11):2198–201.PubMedCrossRefGoogle Scholar
  341. 341.
    DeRosa J, Smit JR. Myxoid malignant fibrous histiocytoma presenting as a midline nasal mass. Ear Nose Throat J. 2012;91(4):E3–5.PubMedGoogle Scholar
  342. 342.
    Carstens HB. Membrane-bound cytoplasmic crystals, similar to those in alveolar soft part sarcoma, in a human muscle spindle. Ultrastruct Pathol. 1990;14(5):423–8.PubMedCrossRefGoogle Scholar
  343. 343.
    Mathew T. Evidence supporting neural crest origin of an alveolar soft part sarcoma: an ultrastructural study. Cancer. 1982;50(3):507–14.PubMedCrossRefGoogle Scholar
  344. 344.
    Machinami R, Kikuchi F. Adenosine triphosphatase activity of crystalline inclusions in alveolar soft part sarcoma. An ultrahistochemical study of a case. Pathol Res Pract. 1986;181(3):357–64.PubMedCrossRefGoogle Scholar
  345. 345.
    Tallini G, Parham DM, Dias P, Cordon-Cardo C, Houghton PJ, Rosai J. Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. Am J Pathol. 1994;144(4):693–701.PubMedPubMedCentralGoogle Scholar
  346. 346.
    Rosai J, Dias P, Parham DM, Shapiro DN, Houghton P. MyoD1 protein expression in alveolar soft part sarcoma as confirmatory evidence of its skeletal muscle nature. Am J Surg Pathol. 1991;15(10):974–81.PubMedCrossRefGoogle Scholar
  347. 347.
    McBiles M, Lambert AT, Cote MG, Kim SY. Sestamibi parathyroid imaging. Semin Nucl Med. 1995;25(3):221–34.PubMedCrossRefGoogle Scholar
  348. 348.
    Arici C, Cheah WK, Ituarte PH, Morita E, Lynch TC, Siperstein AE, et al. Can localization studies be used to direct focused parathyroid operations? Surgery. 2001;129(6):720–9.PubMedCrossRefGoogle Scholar
  349. 349.
    Reiher AE, Schaefer S, Chen H, Sippel RS. Does the final intraoperative PTH level really have to fall into the normal range to signify cure? Ann Surg Oncol. 2012;19(6):1862–7.PubMedCrossRefGoogle Scholar
  350. 350.
    Garner SC, Leight Jr GS. Initial experience with intraoperative PTH determinations in the surgical management of 130 consecutive cases of primary hyperparathyroidism. Surgery. 1999;126(6):1132–7; discussion 7–8.PubMedCrossRefGoogle Scholar
  351. 351.
    Hawkins EP. Pathology of germ cell tumors in children. Crit Rev Oncol Hematol. 1990;10(2):165–79.PubMedCrossRefGoogle Scholar
  352. 352.
    Azizkhan RG, Haase GM, Applebaum H, Dillon PW, Coran AG, King PA, et al. Diagnosis, management, and outcome of cervicofacial teratomas in neonates: a Childrens Cancer Group study. J Pediatr Surg. 1995;30(2):312–6.PubMedCrossRefGoogle Scholar
  353. 353.
    Dehner LP, Mills A, Talerman A, Billman GF, Krous HF, Platz CE. Germ cell neoplasms of head and neck soft tissues: a pathologic spectrum of teratomatous and endodermal sinus tumors. Hum Pathol. 1990;21(3):309–18.PubMedCrossRefGoogle Scholar
  354. 354.
    Tapper D, Lack EE. Teratomas in infancy and childhood. A 54-year experience at the Children’s Hospital Medical Center. Ann Surg. 1983;198(3):398–410.PubMedPubMedCentralCrossRefGoogle Scholar
  355. 355.
    Wakhlu A, Wakhlu AK. Head and neck teratomas in children. Pediatr Surg Int. 2000;16(5–6):333–7.PubMedCrossRefGoogle Scholar
  356. 356.
    Stephenson JA, Mayland DM, Kun LE, Etcubanas E, Thompson EI, Gross CW. Malignant germ cell tumors of the head and neck in childhood. Laryngoscope. 1989;99(7 Pt 1):732–5.PubMedGoogle Scholar
  357. 357.
    Carr MM, Thorner P, Phillips JH. Congenital teratomas of the head and neck. J Otolaryngol. 1997;26(4):246–52.PubMedGoogle Scholar
  358. 358.
    Jordan RB, Gauderer MW. Cervical teratomas: an analysis. Literature review and proposed classification. J Pediatr Surg. 1988;23(6):583–91.PubMedCrossRefGoogle Scholar
  359. 359.
    Batsakis JG, el-Naggar AK, Luna MA. Teratomas of the head and neck with emphasis on malignancy. Ann Otol Rhinol Laryngol. 1995;104(6):496–500.PubMedCrossRefGoogle Scholar
  360. 360.
    Mirshemirani A, Khaleghnejad A, Mohajerzadeh L, Samsami M, Hasas Yeganeh S. Congenital nasopharyngeal teratoma in a neonate. Iran J Pediatr. 2011;21(2):249–52.PubMedPubMedCentralGoogle Scholar
  361. 361.
    Hullett BJ, Shine NP, Chambers NA. Airway management of three cases of congenital cervical teratoma. Paediatr Anaesth. 2006;16(7):794–8.PubMedCrossRefGoogle Scholar
  362. 362.
    Touran T, Applebaum H, Frost DB, Richardson R, Taber P, Rowland J. Congenital metastatic cervical teratoma: diagnostic and management considerations. J Pediatr Surg. 1989;24(1):21–3.PubMedCrossRefGoogle Scholar
  363. 363.
    Shoenfeld A, Ovadia J, Edelstein T, Liban E. Malignant cervical teratoma of the fetus. Acta Obstet Gynecol Scand. 1982;61(1):7–12.PubMedCrossRefGoogle Scholar
  364. 364.
    Batsakis J, Littler E, Oberman H. Teratomas of the neck: a clinicopathologic appraisal. Arch Orolaryngol. 1964;79:619–24.CrossRefGoogle Scholar
  365. 365.
    Ueno S, Hirakawa H, Matsuda H, Tei E, Kaneko A, Ohta Y, et al. A case of neonatal mature teratoma transformed to malignancy in the neck extending to the mouth floor. Tokai J Exp Clin Med. 2009;34(4):130–4.PubMedGoogle Scholar
  366. 366.
    Lack EE. Extragonadal germ cell tumors of the head and neck region: review of 16 cases. Hum Pathol. 1985;16(1):56–64.PubMedCrossRefGoogle Scholar
  367. 367.
    Grosfeld JL, Billmire DF. Teratomas in infancy and childhood. Curr Probl Cancer. 1985;9(9):1–53.PubMedCrossRefGoogle Scholar
  368. 368.
    Krolls SO, Trodahl JN, Boyers RC. Salivary gland lesions in children. A survey of 430 cases. Cancer. 1972;30(2):459–69.PubMedCrossRefGoogle Scholar
  369. 369.
    Muenscher A, Diegel T, Jaehne M, Ussmuller J, Koops S, Sanchez-Hanke M. Benign and malignant salivary gland diseases in children A retrospective study of 549 cases from the Salivary Gland Registry, Hamburg. Auris Nasus Larynx. 2009;36(3):326–31.PubMedCrossRefGoogle Scholar
  370. 370.
    Thariat J, Vedrine PO, Orbach D, Marcy PY, Badoual C, Butori C, et al. Salivary gland tumors in children. Bull Cancer. 2011;98(7):847–55.PubMedGoogle Scholar
  371. 371.
    Shapiro NL, Bhattacharyya N. Clinical characteristics and survival for major salivary gland malignancies in children. Otolaryngol Head Neck Surg. 2006;134(4):631–4.PubMedCrossRefGoogle Scholar
  372. 372.
    Ribeiro Kde C, Kowalski LP, Saba LM, de Camargo B. Epithelial salivary glands neoplasms in children and adolescents: a forty-four-year experience. Med Pediatr Oncol. 2002;39(6):594–600.PubMedCrossRefGoogle Scholar
  373. 373.
    Saunders Jr JR, Hirata RM, Jaques DA. Salivary glands. Surg Clin North Am. 1986;66(1):59–81.PubMedGoogle Scholar
  374. 374.
    Orvidas LJ, Kasperbauer JL, Lewis JE, Olsen KD, Lesnick TG. Pediatric parotid masses. Arch Otolaryngol Head Neck Surg. 2000;126(2):177–84.PubMedCrossRefGoogle Scholar
  375. 375.
    da Cruz Perez DE, Pires FR, Alves FA, Almeida OP, Kowalski LP. Salivary gland tumors in children and adolescents: a clinicopathologic and immunohistochemical study of fifty-three cases. Int J Pediatr Otorhinolaryngol. 2004;68(7):895–902.PubMedCrossRefGoogle Scholar
  376. 376.
    Kupferman ME, de la Garza GO, Santillan AA, Williams MD, Varghese BT, Huh W, et al. Outcomes of pediatric patients with malignancies of the major salivary glands. Ann Surg Oncol. 2010;17(12):3301–7.PubMedCrossRefGoogle Scholar
  377. 377.
    Venkateswaran L, Gan YJ, Sixbey JW, Santana VM. Epstein-Barr virus infection in salivary gland tumors in children and young adults. Cancer. 2000;89(2):463–6.PubMedCrossRefGoogle Scholar
  378. 378.
    Hicks J, Flaitz C. Mucoepidermoid carcinoma of salivary glands in children and adolescents: assessment of proliferation markers. Oral Oncol. 2000;36(5):454–60.PubMedCrossRefGoogle Scholar
  379. 379.
    Spiro R, Spiro J. Salivary gland tumors. Head and neck cancer. Site-specific problems. Prob Gen Surg. 1988(5):217.Google Scholar
  380. 380.
    Callender DL, Frankenthaler RA, Luna MA, Lee SS, Goepfert H. Salivary gland neoplasms in children. Arch Otolaryngol Head Neck Surg. 1992;118(5):472–6.PubMedCrossRefGoogle Scholar
  381. 381.
    Tran L, Sadeghi A, Hanson D, Juillard G, Mackintosh R, Calcaterra TC, et al. Major salivary gland tumors: treatment results and prognostic factors. Laryngoscope. 1986;96(10):1139–44.PubMedCrossRefGoogle Scholar
  382. 382.
    Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer. 2005;103(12):2544–50.PubMedCrossRefGoogle Scholar
  383. 383.
    Bell RB, Dierks EJ, Homer L, Potter BE. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg. 2005;63(7):917–28.PubMedCrossRefGoogle Scholar
  384. 384.
    Levine SB, Potsic WP. Acinic cell carcinoma of the parotid gland in children. Int J Pediatr Otorhinolaryngol. 1986;11(3):281–6.PubMedCrossRefGoogle Scholar
  385. 385.
    Conley J, Tinsley Jr PP. Treatment and prognosis of mucoepidermoid carcinoma in the pediatric age group. Arch Otolaryngol. 1985;111(5):322–4.PubMedCrossRefGoogle Scholar
  386. 386.
    Castro EB, Huvos AG, Strong EW, Foote Jr FW. Tumors of the major salivary glands in children. Cancer. 1972;29(2):312–7.PubMedCrossRefGoogle Scholar
  387. 387.
    Rutt AL, Hawkshaw MJ, Lurie D, Sataloff RT. Salivary gland cancer in patients younger than 30 years. Ear Nose Throat J. 2011;90(4):174–84.PubMedGoogle Scholar
  388. 388.
    Levine PH, Connelly RR, Easton JM. Demographic patterns for nasopharyngeal carcinoma in the United States. Int J Cancer. 1980;26(6):741–8.PubMedCrossRefGoogle Scholar
  389. 389.
    Ayan I, Altun M. Nasopharyngeal carcinoma in children: retrospective review of 50 patients. Int J Radiat Oncol Biol Phys. 1996;35(3):485–92.PubMedCrossRefGoogle Scholar
  390. 390.
    Plowman P. Rare tumors. In: Pinkerton C, Plowman P, editors. Paediatric oncology. Cambridge: Chapman and Hall; 1997.Google Scholar
  391. 391.
    Fandi A, Cvitkovic E. Biology and treatment of nasopharyngeal cancer. Curr Opin Oncol. 1995;7(3):255–63.PubMedCrossRefGoogle Scholar
  392. 392.
    Cvitkovic E, Bachouchi M, Armand JP. Nasopharyngeal carcinoma. Biology, natural history, and therapeutic implications. Hematol Oncol Clin North Am. 1991;5(4):821–38.PubMedGoogle Scholar
  393. 393.
    Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet. 1997;350(9084):1087–91.PubMedCrossRefGoogle Scholar
  394. 394.
    Chan AS, To KF, Lo KW, Mak KF, Pak W, Chiu B, et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res. 2000;60(19):5365–70.PubMedGoogle Scholar
  395. 395.
    Claudio PP, Howard CM, Fu Y, Cinti C, Califano L, Micheli P, et al. Mutations in the retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma. Cancer Res. 2000;60(1):8–12.PubMedGoogle Scholar
  396. 396.
    Sheu LF, Chen A, Meng CL, Ho KC, Lin FG, Lee WH. Analysis of bcl-2 expression in normal, inflamed, dysplastic nasopharyngeal epithelia, and nasopharyngeal carcinoma: association with p53 expression. Hum Pathol. 1997;28(5):556–62.PubMedCrossRefGoogle Scholar
  397. 397.
    Hildesheim A, Anderson LM, Chen CJ, Cheng YJ, Brinton LA, Daly AK, et al. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 1997;89(16):1207–12.PubMedCrossRefGoogle Scholar
  398. 398.
    Fernandez CH, Cangir A, Samaan NA, Rivera R. Nasopharyngeal carcinoma in children. Cancer. 1976;37(6):2787–91.PubMedCrossRefGoogle Scholar
  399. 399.
    Ozyar E, Atahan IL, Akyol FH, Gurkaynak M, Zorlu AF. Cranial nerve involvement in nasopharyngeal carcinoma: its prognostic role and response to radiotherapy. Radiat Med. 1994;12(2):65–8.PubMedGoogle Scholar
  400. 400.
    Woollons AC, Morton RP. When does middle ear effusion signify nasopharyngeal cancer? N Z Med J. 1994;107(991):507–9.PubMedGoogle Scholar
  401. 401.
    Serin M, Erkal HS, Elhan AH, Cakmak A. Nasopharyngeal carcinoma in childhood and adolescence. Med Pediatr Oncol. 1998;31(6):498–505.PubMedCrossRefGoogle Scholar
  402. 402.
    Sultan I, Casanova M, Ferrari A, Rihani R, Rodriguez-Galindo C. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr Blood Cancer. 2010;55(2):279–84.PubMedCrossRefGoogle Scholar
  403. 403.
    Uzel O, Yoruk SO, Sahinler I, Turkan S, Okkan S. Nasopharyngeal carcinoma in childhood: long-term results of 32 patients. Radiother Oncol. 2001;58(2):137–41.PubMedCrossRefGoogle Scholar
  404. 404.
    Cheuk DK, Sabin ND, Hossain M, Wozniak A, Naik M, Rodriguez-Galindo C, et al. PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2012;39(7):1097–106.PubMedPubMedCentralCrossRefGoogle Scholar
  405. 405.
    Geara FB, Glisson BS, Sanguineti G, Tucker SL, Garden AS, Ang KK, et al. Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer. 1997;79(7):1279–86.PubMedCrossRefGoogle Scholar
  406. 406.
    Ahern V, Jenkin D, Banerjee D, Greenberg M, Payne D. Nasopharyngeal carcinoma in the young. Clin Oncol (R Coll Radiol). 1994;6(1):24–30.CrossRefGoogle Scholar
  407. 407.
    Casanova M, Bisogno G, Gandola L, Cecchetto G, Di Cataldo A, Basso E, et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project. Cancer. 2012;118(10):2718–25.PubMedCrossRefGoogle Scholar
  408. 408.
    Buehrlen M, Zwaan CM, Granzen B, Lassay L, Deutz P, Vorwerk P, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012;118(19):4892–900.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Department of Pediatric SurgeryChildren’s Medical CenterDallasUSA
  2. 2.Department of SurgeryChildren’s Medical Center of DallasDallasUSA

Personalised recommendations